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Acromegaly caused by ectopic growth hormone–releasing hormone
secretion by a carcinoid bronchial tumor: A rare entity
Kalliopi Athanassiadi, MD,a Dimitrios Exarchos, MD,b Stylianos Tsagarakis, MD,c and Ion Bellenis, MD,a Athens, Greece
Ectopic secretion of growth hormone–releasing hormone(GHRH) is a rare cause of acromegaly.1-5 The mostcommon tumors secreting GHRH are bronchial carci-noids and pancreatic islet cell tumors. Differential di-
agnosis of pituitary adenoma is necessary to avoid unnecessary
pituitary surgery and damage to the pituitary gland. Rarely, that
syndrome is secondary to a carcinoid bronchial tumor. We present
a case of a synchronous GHRH-secreting bronchial carcinoid and
a pituitary adenoma in a patient with acromegaly.
Clinical Summary
A 37-year-old man who presented with an acromegaly over the last
8-year period was hospitalized in our department. He had been
treated surgically for an acidophil pituitary adenoma 1 year ago,
and the histology had revealed an adenoma (1.3 cm  1.3 cm)
producing growth hormone (GH) and prolactin. There was no
amelioration of the clinical signs of acromegaly postoperatively,
and the GH and insulin-like growth factor levels, although lower,
reached 50 ng/mL and 833 ng/mL, respectively. The glucose
tolerance test indicated diabetes. Thyroid and parathyroid hor-
mones were within normal levels.
The patient was subjected to magnetic resonance imaging,
which showed remaining pathologic pituitary tissue. Sandostatin
was administered in subcutaneous doses of 100 g 3 times because
during the test of somatostatin, there had been a tremendous
suppression of GH levels. The response to sandostatin was remark-
able, but acromegaly was still active, and the patient was submitted
to radiation of the pituitary region with Co60 in a total dose of
5000 Gy (200 Gy daily).
Six months later, the patient was re-examined and was found to
still have active acromegaly while receiving medication. His chest
x-ray film demonstrated a large tumor of the left lung. Computed
tomographic scanning revealed a large circumscribed tumor in the
left upper lobe without lymph node enlargement. Angiography was
undertaken before surgical intervention to exclude angioma or
arteriovenous malformation (Figure 1). The patient underwent a
left upper lobectomy (Figure 2). Histology demonstrated a carci-
noid tumor of 6  5.5  4.5 cm without cellular atypia or any
features of malignancy. The bronchial carcinoid was tested immu-
nohistochemically and was found to be positive for gastrin and
somatostatin secretion.
One month later, the basal GH levels decreased to 3.5 ng/mL,
the amelioration of the clinical signs was obvious, and the patient
recovered completely within 6 months.
Discussion
Acromegaly caused by ectopic GHRH secretion by carcinoids is a
rare cause of GH hypersecretion. This diagnosis should be sus-
pected in any case of proved acromegaly in which there is no clear
evidence of pituitary adenoma.1 Of the 39 fully documented cases
of acromegaly caused by extracranial tumors synthesizing GHRH
recognized by Faglia and colleagues,3 21 were bronchial carci-
noids. Occasionally, carcinoid and pituitary adenomas coexist as
parts of a widespread pluriglandular syndrome.5
This case differs from the others described in the literature
because apart from the bronchial carcinoid, a pituitary adenoma
coexisted and not a hyperplasia, as is mentioned in other reports.4,5
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Figure 1. Angiography demonstrating a rich vascularized carci-
noid tumor.
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The patient’s sex also differs. He was a man, and it is clearly stated
in the literature that ectopic acromegaly is more often seen in
women younger than 40 years.4
Unfortunately, the neuroendocrine tests cannot differentiate
between ectopic GHRH secretion and pituitary adenoma.1 High
GH plasma levels and excessive production of GHRH can be
suggestive of ectopic secretion, with the exception of very rare
cases of excessive GHRH of hypothalamic origin.2 The somatosta-
tin receptor scintigraphy could have been an alternative diagnostic
tool, but it was not performed in our case.
In inoperable cases or incomplete operations, octreotide seems
to be effective.5 Surgical excision of the bronchial carcinoid tumor
leads to a rapid decrease of GHRH and to a benign clinical course,
as is also mentioned in other reports.1,2
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Innominate artery transection in the setting of a bovine arch
Mireille A. Moise, MD,a Vivian Hsu, BA,a Benjamin Braslow, MD,b and Y. Joseph Woo, MD,a Philadelphia, Pa
Blunt trauma to the innominate artery is an infrequentbut commonly fatal occurrence. We report a case of apatient with a bovine arch who underwent successfulgraft replacement of the innominate artery and recon-
struction of the aortic arch under deep hypothermic circulatory
arrest with retrograde cerebral perfusion.
Clinical Summary
A 46-year-old woman was brought to our trauma bay intubated
with stable hemodynamics after a head-on motor vehicle collision.
A chest x-ray film showed a widened mediastinum. A subsequent
computed tomographic scan of the chest and aortogram revealed a
contained traumatic pseudoaneurysm of the innominate artery in
the setting of bovine arch anatomy (Figure 1). The patient also had
a grade III liver laceration, bilateral rib fractures leading to bilat-
eral pneumothoraces, and multiple lower extremity orthopedic
injuries. She was taken on an emergency basis to the operating
room. An external fixation device was placed to stabilize the right
femur and to prevent further blood loss in that compartment. A
baseline focused abdominal sonographic exam for trauma was then
performed and repeated every 30 minutes to exclude the presence
of intraperitoneal hemorrhage from the liver laceration in the
setting of heparinization for cardiopulmonary bypass. A median
sternotomy was performed, and cardiopulmonary bypass was ini-
tiated via ascending aortic and right atrial cannulation. Circulatory
arrest with retrograde cerebral perfusion at a flow rate of 250 to
350 mL/min and a central venous pressure of 21 to 23 mm Hg was
initiated at a core bladder temperature of 15°C (Figure 2, A). One
gram of methylprednisolone sodium succinate (Solu-Medrol) was
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Figure 2. The well-encapsulated large tumor.
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